StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a report released on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a one year low of $0.00 and a one year high of $0.00. The firm has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Read More
- Five stocks we like better than Genocea Biosciences
- What is a Special Dividend?
- Comprehensive PepsiCo Stock Analysis
- Why Invest in 5G? How to Invest in 5G Stocks
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.